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ABSTRACT
Circulating Tumor Cells (CTCs) represent a “liquid biopsy” of the tumor potentially 
allowing real-time monitoring of cancer biology and therapies in individual patients.
The purpose of the study was to explore the applicability of a protocol for the 
molecular characterization of single CTCs by Next Generation Sequencing (NGS) in order 
to investigate cell heterogeneity and provide a tool for a personalized medicine approach.
CTCs were enriched and enumerated by CellSearch in blood from four metastatic 
breast cancer patients and singularly isolated by DEPArray. Upon whole genome 
amplification 3–5 single CTCs per patient were analyzed by NGS for 50 cancer-related 
genes.
We found 51 sequence variants in 25 genes. We observed inter- and intra-patient 
heterogeneity in the mutational status of CTCs.
The highest number of somatic deleterious mutations was found in the gene 
TP53, whose mutation is associated with adverse prognosis in breast cancer.
The discordance between the mutational status of the primary tumor and CTCs 
observed in 3 patients suggests that, in advanced stages of cancer, CTC characteristics 
are more closely linked to the dynamic modifications of the disease status.
In one patient the mutational profiles of CTCs before and during treatment shared 
only few sequence variants.
This study supports the applicability of a non-invasive approach based on the 
liquid biopsy in metastatic breast cancer patients which, in perspective, should allow 
investigating the clonal evolution of the tumor for the development of new therapeutic 
strategies in precision medicine.
INTRODUCTION
Recent researches on cancer tried to explain all the 
characteristics of a tumor in a single individual focusing 
on the clinical relevance of tumor heterogeneity [1]. 
Notwithstanding the huge progress in elucidating cancer 
biology and genetics of the last decade, it is still difficult 
to translate into clinical practice the acquired knowledge 
on the emerging cellular complexity of the tumors and 
their dynamic features [2]. An open question in cancer 
biology is related to the use of appropriate tools to 
describe intratumoral heterogeneity and recent technologic 
advances in modern pathology have made it possible to 
analyze nucleic acids and proteins from different areas of 
a single tumor as well as from different cell types within 
the tumor, reaching the single cell resolution.
New advances in single–cell technology might 
help to achieve a deeper biological insight on cancer 
development and progression by analyzing the roles of 
individual cells in health and disease. Single-cell analysis is 
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suitable to disclose information from rare cell types within 
a tissue or a biological fluid in order to avoid the averaging 
of bulk analysis and to capture the heterogeneity of cells.
Circulating tumor cells (CTCs) shed by the primary 
tumor as well as metastases during tumor formation and 
progression are now considered a real-time “liquid biopsy” 
reflecting the disease complexity [3]. So far the studies on 
CTCs have been focused on their prognostic significance, their 
utility in real-time monitoring of therapies, the identification 
of therapeutic targets and resistance mechanisms, and 
understanding the metastatic process [3]. Recently it has 
been assessed that the molecular characterization of CTCs is 
pivotal to increasing the diagnostic specificity of CTC assays 
and investigating therapeutic targets and their downstream 
pathways on CTCs [4].
Although we already know that CTCs are genetically 
heterogeneous [4–9], single-cell analysis of CTCs is the 
definitive and most reliable method to evidence this feature 
getting read of the interference from nucleated blood 
cells, avoiding loss of sensitivity due to the averaging 
that derives from the analysis of pooled samples, and 
understanding if the detected variants coexist in a single 
cell or derive from multiple cell clones [10]. Recent 
advances in Next Generation Sequencing (NGS) and 
Whole Genome Amplification (WGA) methods allow 
single cell analysis [11]. Single cells technologies are now 
playing an increasing role in the analysis of CTCs and 
will help the development of new therapeutic concepts in 
personalized medicine [12].
The presence of CTCs in early stage and metastatic 
breast cancer is associated with poor survival. While some 
authors already provided evidences for the prognostic 
relevance of CTCs in early breast cancer [13], data on 
CTCs in different subtypes of non-metastatic breast 
cancer are still inconsistent [14]. On the contrary, in 
advanced breast cancer the prognostic value of CTCs has 
been clearly demonstrated. In particular, CTC detection 
in baseline conditions has been shown as an independent 
predictor of progression-free survival and overall 
survival [15–17]. Moreover, a substantial decrease in the 
CTC count is an early marker of individual response to 
treatment and thus CTC screening provides an easy-to-
perform alternative method to monitor the success of a 
given therapy [18].
A high number of ongoing clinical trials involve 
CTCs in order to evaluate the phenotype of persisting 
tumor cells, the benefits of secondary treatments and the 
survival upon additional adjuvant treatments in high risk 
patients [19] as well as the role of CTCs as markers of 
early prediction of treatment efficacy [20].
More studies are needed to clarify the clinical 
utility of CTC burden determination in the management 
of the oncologic patient [21]. To move forward in the 
evaluation of CTCs as surrogate biomarkers for tumor 
progression a further characterization of CTC biology is 
required, including refining and improving cell isolation 
methods. In fact, some contradictory results on CTCs 
achieved by different research groups can be attributed 
to the use of CTC detection methods based on several 
principles, varying from indirect PCR-based methods 
to cytomorphological identification of the tumor cells 
circulating in blood. Until recently, the CellSearch® 
system has been considered as the reference method 
for CTC counting, but it still lacks a solution to allow a 
reliable downstream molecular characterization of the 
cells. Schneck et al. [22] proposed to recover the entire 
content of the CellSearch® cartrigdes (including residual 
white blood cells) for the molecular analysis of PIK3CA 
mutations by a snapshot technique, while more recently a 
novel method for downstream characterization of breast 
cancer circulating tumor cells by a triple-immunostaining 
following CellSearch® isolation has been published [23].
To overcome the averaging approach determined 
by the use of bulk CTC analysis, single cell isolation can 
be achieved only by sophisticated instrumentation which 
requires expert operators and time consuming protocols 
which only seldom can guarantee the single cell level. We 
chose a dieletrophoretic method (DEPArray™ system, 
Silicon Biosystems, Italy) to obtain single CTCs or pools 
of pure cells avoiding the inferences from leucocytes 
which are still present in a much higher proportion than 
CTCs. Recently we demonstrated the possibility of 
sequencing single CTCs form metastatic breast cancer 
patients by Sanger method [8]. The same workflow 
involving CellSearch® enrichment followed by single 
cell sorting using DEPArray™ was assessed by Polzer 
and co-workers [24] who performed aCGH and Sanger 
sequencing on single CTCs from breast cancer patients.
Another approach combines the CellSearch® with 
a flow-sorting protocol allowing genomic profiling at the 
single cell level [25] and demonstrating the suitability 
of some FACS (Fluorescence-Activated Cell Sorting) 
instruments for single-cell sorting.
With the present study we aim at exploring the 
applicability of a protocol for the molecular characterization 
of single CTCs by Next Generation Sequencing in order to 
investigate cell heterogeneity and to identify a new tool for 
a personalized medicine approach to patients.
In fact, in order to transfer data on CTC characterization 
to the clinic, the practicability and reliability of a standardized 
procedure represent the first issue to be verified.
RESULTS
Patient and tumor characteristics
Three patients had HER2 negative ER positive 
primary tumors and one patient had a triple negative 
primary breast cancer. Two patients had metastatic disease 
at diagnosis and were untreated before blood sampling, 
while the remaining two patients received five and one 
lines of systemic therapies for metastatic breast cancer 
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(MBC) before blood sampling, respectively. Clinical and 
pathological characteristics are summarized in Table 1.
Quality control of the experimental procedure
The proposed workflow included several steps 
of quality control at the level of CTC enrichment by 
CellSearch®, whole genome amplification of single CTCs 
isolated by DEParray™ and single cell sequencing by NGS. 
The single steps of the quality assessment are described 
in the Materials and Methods section. Only samples 
that passed the quality controls were submitted to the 
subsequent analyses. Moreover we had previously verified 
the entire workflow on an artificial sample obtained by 
spiking a known number of cells from a breast cancer cell 
line into the blood from a healthy donor [26].
Next Generation Sequencing on single CTCs
Results have been obtained by the experimental 
workflow described in details in the Materials and 
Methods section and illustrated in Figure 1.
Figure 2 reports an example of a single CTC from 
one of the patients of the case study as it appears in the 
DEPArray™ image gallery.
On the whole, we sequenced 14 CTCs from 
4 patients with a mean depth of 1500X ranging from 
1046X to 2478X depth of coverage for each amplicon per 
sample. According to the literature we analyzed sequence 
variants having at least 100X coverage [27].
Overall we found 51 sequence variants in 25 genes 
of the panel. In particular, patient 1 (the only patient 
for whom five CTCs were available for the analysis) 
showed the highest number of sequence variants (30 
variants in 20 genes), while patients 2, 3 and 4 presented 
10 variants in 6 genes, 3 variants in 3 genes and 
8 variants in 7 genes, respectively (Table 2). Of note, 
patient 1, characterized by the highest number of 
gene mutations and sequence variants, achieved a 
long-lasting response to a line of chemotherapy with 
capecitabine-vinerolbine (Figure 3).
Among the 51 identified sequence variants, 22 were 
already described in the COSMIC or HGMD databases, 
while 29 have never been reported before (Figure 4A). 
Table 2 reports the sequence variants found in each CTC. 
Thirty-eight variants were classified as having possible 
deleterious consequences on the protein phenotype 
according to the Polyphen-2 or SIFT software, while 
13 were supposed benign (Figure 4B).
The gene with the highest number of deleterious 
somatic mutations was TP53 (8 mutations) followed by 
PDGFRA (3 mutations).
No sequence variant was common to different 
patients. The major part of somatic mutations was usually 
detected in only 1 single CTC from 1 patient revealing a 
high intra- and inter- patient heterogeneity (Table 2). Only 
the following sequence variants were present in two or 
more CTCs from the same patient:
• p.V777L in exon 20 of the ERBB2 gene;
• p.A189_P190 > X in exon 5 of the TP53 gene;
• p.Q192X in exon 5 of the TP53 gene;
• p.R273C in exon 7 of the TP53 gene;
• p.M541L in exon 10 of the KIT gene;
• p.V824V in exon 17 of the PDGFRA gene.
Among the variants listed above we selected those 
found in the ERBB2 and TP53 genes for a validation by 
Sanger sequencing. All the variants evidenced by NGS 
were confirmed by Sanger on the same samples.
Comparison between CTCs and primary tissues
In three patients we could compare the NGS results 
from CTCs with those from the primary tissue (Table 3) 
limited to the variants found in the single CTCs.
In patient 2 the benign variant p.V824V in the 
PDGFRA gene was found in both CTCs and FFPE tissue.
The only deleterious somatic mutations detected 
in both CTCs and tissue were the p.R273C in the TP53 
gene in patient 4 and p.A189_P190 > X plus p.Q192X in 
exon 5 of the TP53 gene in patient 2. All the other variants 
discovered in CTCs were not present in the corresponding 
primary tissue.
Comparison between CTCs isolated before and 
after treatment
In patient 1 a second blood sample, drawn 1 month 
after the start of treatment, was analysed, allowing a 
comparison of the mutational profile of CTCs before and 
during treatment (Table 4).
Only two sequence variants, p.V777L in ERBB2 
and p.M541L in KIT, were detected before and during 
therapy in all the analysed CTCs. All the other variants 
described in patient 1 at baseline were not detected while 
on treatment.
The following 8 somatic mutations were detected in 
CTCs only while on treatment:
• p.P281T in exon 7 of the EGFR gene;
• p.V384L in exon 9 of the ERBB4 gene;
• p.K313E in exon 6 of the FGFR2 gene;
• p.S326Y in exon 4 of the PIK3CA gene;
• p.H528R in exon 11 of the SMAD4 gene;
•  p.D172G and p.L191L in exon 3 of the SMARCB1 
gene;
• p.C162R in exon 3 of the VHL gene.
All the mutations were identified in only one out of 
three CTCs.
Oncotarget26110www.impactjournals.com/oncotarget
DISCUSSION
Our study represents an implementation of a 
workflow for the molecular characterization of single 
CTCs by massive parallel sequencing.
Our purpose was to perform a pilot study on a 
limited number of samples to assess the applicability of the 
analysis of a panel of genes by NGS in single circulating 
tumor cells from breast cancer patients.
The proposed approach, combining CellSearch and 
DEPArray, had previously been applied to samples from 
cancer patients by Polzer and coworkers [24], Fernandez 
et al. [7] and ourselves [8] but had never been tested before 
for isolating single CTCs in view of a NGS analysis. 
Moreover, in the study by Neves et al. [25] single cells 
sorted by the use of a particular FACS instrument have 
been analyzed by aCGH which can provide evidences of 
chromosomal aberrations and copy number variations but 
is unable to perform the analysis of single point mutations 
as provided by the NGS approach.
The Ion AmpliSeq™ Cancer Hotspot Panel v2 is not 
focused on breast cancer, but it is designed as a tool to be 
used in any kind of cancer. Nonetheless we found several 
somatic mutations in ERBB2, PIK3CA, PTEN, RB1, 
SMAD4 and TP53, genes already described as bearing 
driver mutations in breast cancer [28].
The highest number of somatic deleterious 
mutations was not surprisingly found in the tumor 
suppressor gene TP53, whose mutation is associated with 
adverse prognosis in breast cancer [29]. The mutation 
p.R273C in exon 7 of the TP53 gene has been associated 
with enhanced proliferation, invasion, and drug resistance 
in vitro in breast cancer [30].
The mutation p.V777L in exon 20 of the ERBB2 
gene is already described as an activating mutation that 
likely drives tumorigenesis in breast cancer and it can be 
found in 1.6–2.0% of breast cancer patients and in about 
6.0% of ERBB2-mutated patients [31]. When assessing 
sensitization to HER2-targeted therapies, cells with 
this mutation are highly sensitive to neratinib, but less 
sensitive to lapatinib, in a manner similar to wild-type 
HER2, in vitro [31].
Even if we studied a limited number of patients with 
different pathological characteristics, not allowing to draw 
any final conclusion on inter-patient heterogeneity, the 
fact that we did not identify sequence variants common 
to different patients may confirm that each cancer is 
different among individuals and underlines the importance 
of a personalized medicine approach to the single patient. 
Nonetheless, our focus was on intra-patient heterogeneity, 
which can explain the lack of response to targeted agents 
despite the presence of a given biomarker on a tumor 
biopsy. This is a “hot topic” for clinicians evaluating pros 
and cons of the metastatic site biopsy. These preliminary 
data seem to support the “liquid biopsy strategy” as a 
more appropriate tool than the “metastatic site biopsy 
strategy” because biomarkers assessment on individual 
CTCs, potentially released in the blood flow from different 
metastatic sites, can be more informative than biomarkers 
assessment on a single metastatic site biopsy.
Table 1: Patients’ clinical and pathological characteristics
Patient ID 1 2 3 4 
Tumor stage at diagnosis IV IV III III
Histology IDC IDC IDC IDC
ER status (%) 90 0 90 80
PgR Status (%) 70 0 0 80
HER2 status by IHC 0 0 1+ 0
Ki67 (%) 15 40 20 30
Type of adjuvant therapy NA NA CT → HT CT → HT
DFI (months) 0 0 27 119
IMDS (months) 0 0 6 47
No. of prior lines for MBC 0 0 1 4
No. of metastatic sites 3 3 1 3
Presence of bone metastases (Y/N) Y N Y Y
Abbreviations: ER: estrogen receptor; PgR: progesterone receptor; IHC: immunohistochemistry; DFI: disease free interval 
(from date of breast surgery to first relapse); IMDS: interval between diagnosis of metastatic disease and blood sampling; 
; Y: yes; N: no; MBC: metastatic breast cancer; IDC: infiltrating ductal carcinoma; CT: chemotherapy; HT: endocrine 
therapy; NA: not applicable.
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Figure 2: Image of a single CTC isolated from one patient as it appears in the image gallery of the DEPArray™ 
instrument. The cell shows a positive fluorescent signal for DAPI (the DNA intercalating dye) and for the expression of cytokeratins 
(CK), while is negative for CD45.
Figure 1: Workflow for single CTC detection and molecular analysis. Each arrow represents one step of the procedure. Details 
on the methods are reported aside.
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Table 2: Somatic mutations detected in single CTCs
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Almost all the mutations were present in only one 
CTC from the same patient highlighting the importance of 
the analysis at the single cell level; in fact pooling the cells 
might provide different results not reflecting the actual 
heterogeneity of the CTCs. In addition rare mutations in 
a single CTC could be missed by a bulk analysis of the 
sample.
We found discordant results between the mutational 
status of CTCs and that of the corresponding primary 
tissue, probably due to the fact that in advanced stages of 
cancer CTCs reflect the dynamic evolution of the disease 
more closely than the primary tumor, even if we must take 
into account WGA or sequencing artifacts.
Previous studies showed that amplification and 
sequencing errors are a concern for single cell mutation 
analysis [32], but the high coverage reached for our 
samples makes us confident on the reliability of even 
minor variants found only in single samples. In fact 
achieving high physical coverage of the targeted sequences 
is crucial for calling mutations at the same regions across 
multiple single cells [33]. With the Ion Torrent PGM a 
minimum of 100–300X and 20–30X coverage is required 
to identify respectively insertion and deletions; as we 
reached a mean coverage of 1500X per amplicon, we feel 
confident about the reliability of the detected variants.
As far as NGS sequencing errors are concerned, 
a confirmation by Sanger of the identified variants can 
exclude false positive results, even if this laborious low 
throughput approach cannot be extended to all the detected 
variants in a study involving sequencing of a high number 
of genes in different samples. Accordingly, we confirmed 
the presence of some of the most relevant variants by 
Sanger sequencing on the same amplified samples. 
Nevertheless, we suppose that with the widespread use 
of NGS and deeper insights on the technical performance 
of the method especially at the single cell level, Sanger 
sequencing confirmation could be avoided.
As already showed by recently published data 
probing the very high accuracy and sensitivity of PGM 
sequencing, the error rate of the Ion Torrent is lower with 
Figure 3: Patients’ clinical outcome from the time of blood sampling.
Oncotarget26114www.impactjournals.com/oncotarget
respect to other NGS platforms. Anyway, due to the Ion 
Torrent chemistry, the homopolymer sequencing errors 
are known to be an issue, but the examination of our 
experimental results did not reveal any homopolymer-
based errors or any errors caused by the position of the 
mutation in the amplicon. This may be due to the design 
of the primers used in the Cancer Hot Spot panel v2 or the 
location of the mutations [31–35].
However, we cannot formally exclude technical 
errors deriving from the WGA procedure. As already 
pointed out by other authors, WGA could affect 
subsequent sequencing results by introducing a number 
of technical variables such as allelic dropout, inadequate 
coverage, false positive and negative results [33]. For 
this reason we chose to adopt a WGA method which has 
been shown to reliably amplify the entire cellular genome 
homogeneously [36].
In addition we cannot exclude that the sequence 
variants detected in CTCs are present in minor clones 
of the primary tumor, thus under the detection limit of 
sequencing techniques, even though the use of massive 
parallel sequencing with a high coverage also for tissue 
sample analysis should have reduced the number of 
undetected variants. To overcome this problem we could 
resort to alternative methods with a higher sensitivity 
than sequencing techniques such as qPCR, digital PCR or 
COLD PCR, able to detect specific point mutations (but 
not suitable for detecting a higher number of variants at 
a time); alternatively we are convinced that analyzing a 
higher number of CTCs or performing different samplings 
of the tissue could in part solve this issue.
One of the major advantages of the liquid biopsy 
is the possibility of repeating the blood sample at various 
time points during the disease course. Our findings on 
Figure 4: Number of sequence variants identified in the case study. (A) Number of novel/described variants per gene. (B) 
Number of deleterious/benign variants per gene.
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patient 1 seem to indicate that CTC characterization may 
be applied to monitor the response to therapy; in fact CTCs 
collected after treatment share only few variants with 
those of the first blood sample, while they present some 
variants undetectable in baseline conditions. Interestingly 
the mutation p.V777L in exon 20 of the ERBB2 gene 
was common to all the CTCs at baseline and in the post-
therapy condition, indicating that the clone bearing this 
variant was resistant to the administered therapy.
On the whole our results show an extreme 
heterogeneity of the mutational status of single CTCs in 
metastatic breast cancer patients. Among the different somatic 
mutations we can identify druggable variants, but finding 
them in a single CTC raises a question about the utility of 
the analysis and the possibility to use the information for a 
therapeutic intervention. The liquid biopsy in advanced stages 
is representative of the complexity of the disease [3] which is 
difficult to treat. On the other hand monitoring the evolution 
of the disease from early stages by the liquid biopsy could 
help identifying more aggressive clones of CTCs against 
which target therapies could be directed.
We believe that this pilot study supports the 
applicability of the liquid biopsy approach in MBC patients. 
These results provide a rationale for further studies aiming 
to integrate the liquid biopsy in the context of a new 
generation of trials for MBC patients. Our next step will be 
the activation of clinical trials testing the activity of targeted 
therapies and correlating the response to treatment with bio-
markers assessed at the CTC level. In addition, taking into 
account some data suggesting that gene expression profiles 
might be more informative in terms of pathway functional 
status than gene mutations [37], we are now running a pilot 
study aiming to evaluate both gene expression profiles and 
gene mutations from CTCs of MBC patients. We believe 
that this approach might be informative, particularly for 
predicting the activity of new compounds targeting the 
PI3K/AKT/MTOR pathway [37].
In summary, this study supports the feasibility of 
the liquid biopsy strategy in MBC patients and highlights 
the substantial intra-tumor heterogeneity occurring at the 
individual patient level. It is now time to incorporate the 
liquid biopsy approach into a new generation of trials 
aiming to personalize treatment of MBC patients.
MATERIALS AND METHODS
Patients
Ten mL of whole blood were drawn from four 
metastatic breast cancer (MBC) patients attending the “Sandro 
Pitigliani” Medical Oncology Department, Prato Hospital. 
Samples were drawn before starting a systemic therapy and 
were collected in CellSave™ tubes (Veridex LLC).
At the time of blood sampling, patients had not 
received any systemic treatment for at least 3 weeks. The 
study protocol was approved by the ethical committee of 
Table 3: Comparison between CTCs and tissues
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Prato Hospital and all included patients gave a written 
informed consent.
For patient 1, a follow-up sample of 10 ml of whole 
blood was drawn after one month of treatment, collected 
in a CellSave™ tube and processed as described below.
Workflow for the molecular characterization of a 
panel of genes in single CTCs
Figure 1 reports a schematic view of the 
experimental workflow described below.
Table 4: Sequence variants detected in single CTCs from patient 1 before and while on treatment
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CTC enrichment, single CTC recovery and whole 
genome amplification were performed according to a 
protocol already described and validated in a previous 
paper by our research team [8]. The NGS protocol has 
been previously optimized by our research team on 
artificial samples obtained by spiking a breast cancer cell 
line into the blood from a healthy donor [26].
CTC enrichment
CTC enrichment was performed by the CellSearch® 
System. Whole blood (7.5 mL) was processed using the 
CellSearch® Epithelial Cell kit (Veridex LLC), which selects 
EpCAM positive cells using ferrofluids particles coated 
with EpCAM antibody. The procedure involves a specific 
CTC quality control (CELLSEARCH® CTC Control Kit 
consisting of 2 populations of a fixed breast cancer cell line 
at high and low concentration) to be performed together 
with patients’ samples. The quality control kit allows to 
verify the performance of reagents, sample processing 
by the CELLTRACKS® AUTOPREP® System, and cell 
analysis by the CELLTRACKS ANALYZER II® System to 
confirm that system performance is optimal.
Cells were stained with the nuclear dye 4′,6′- 
diamino-2-phenylindole (DAPI), anti-cytokeratin 8, 18 
and 19-phycoerythrin (PE) labelled antibodies, and CD45 
antibody labelled with allophycocyanin (APC). After 
enrichment, isolated and stained cells were resuspended 
in the MagNest Device (Veridex LLC), labelled cells were 
analyzed in the CellTracks® Analyzer II (Veridex LLC) and 
CTCs identified and enumerated according to the criteria 
specified by the manufacturer’s instructions.
Single CTC recovery
Samples enriched by CellSearch® were stored 
protected from light at 4°C before sorting with the 
DEPArray™ (Silicon Biosystems). Each CTC-enriched 
sample was recovered from the Veridex cartridge and 
loaded into the DEPArray™ A300K chip (Silicon 
Biosystems) according to the manufacturer’s instructions. 
The chip was set into the DEPArray™ system. Chip 
scanning was performed by an automated fluorescence 
microscope to generate an image gallery, with cells selected 
according to their morphology (round shape, round nucleus 
within the cytoplasm) and staining pattern deriving from 
that of the CellSearch® system: DAPI positive, PE positive 
(CK8, CK18, CK19 positive cells), APC negative (CD45 
negative cells). After CTC identification, single cells were 
recovered into 200 µl tubes.
Whole Genome Amplification
Single CTCs (3–5 CTCs per patient) were submitted 
to Whole Genome Amplification (WGA) using the 
Ampli1™ WGA kit (Silicon Biosystems) according the 
manufacturer’s instructions, in order to obtain a sample 
suitable for sequencing analysis.
The quality of the output product of the WGA 
reaction was assessed by the Ampli1™ QC kit (Silicon 
Biosystems) according to the manufacturer’s instructions.
Next Generation Sequencing
Sequencing analysis was performed on the Ion Torrent 
PGM™ system (Life Technologies, USA). Samples were 
amplified using the Ion AmpliSeq™ Cancer Hotspot Panel v2 
(Life Technologies) designed to target 207 amplicons covering 
mutations from 50 oncogenes and tumor suppressor genes. 
DNA quantification was assessed using Qubit 2.0 Fluorometer 
(Life Technologies). Ten nanograms of DNA were used to 
prepare barcoded libraries using the Ion AmpliSeq™Library 
kit 2.0 and Ion Xpress™ barcode adapters (Life 
Technologies). The libraries were purified with Agentcourt 
AMPure XP (Beckman Coulter, USA) and quantified with 
Ion Library Quantitation Kit (Life Technologies) on StepOne 
Plus system (Applied Biosystems, USA).
Template preparation was performed with the Ion 
OneTouch™ 2 System and Ion One Touch ES. Finally 
sequencing was performed on PGM using Ion PGM™ 
Sequencing 200 kit v2 (Life Technologies) on Ion 316 
chip V1. The run was set in order to achieve a 1000X 
coverage for each sample.
We performed a quality control (QC) of the 
NGS procedure according to the following steps: 1) 
quantification of the DNA samples through a fluorimetric 
assay by Qubit Fluorometer; 2) QC after the clonal 
amplification in the emulsion PCR, by a fluorimetric assay 
that determines the percentage of the Ion Sphere Particles 
templated samples; 3) QC by the Torrent Suite after the 
run, this analysis gives information about the performance 
of the run and the quality of the generated sequencing data.
Data analysis
All samples were processed using the Torrent Suite 
Software 3.6 and variant calling was performed running 
the Torrent Variant Caller plugin version 3.6.56708. 
Moreover, samples were analyzed using the NextGENe® 
software 2.3.1 (SoftGenetics, LLC, USA).
Each variant was investigated about its potential 
pathogenetic role using available gene mutations and 
SNPs databases and prediction algorithms (COSMIC, 
dbSNP, 1000GENOME, SIFT, Polyphen).
NGS on DNA from formalin-fixed paraffin 
embedded (FFPE) tissues
For three patients a formalin-fixed paraffin-
embedded (FFPE) primary tumor tissue block with a 
representative invasive part (at least 50% of cells) was 
available.
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DNA from 10 slides of 4 μm tumor tissue sections 
was extracted using the FFPE Tissue kit (QIAgen, 
Germany). The appropriate protocol to construct the 
libraries according to the Ion AmpliSeq™ DNA and RNA 
Library Preparation manual (Revision B.0) was adopted. 
Sequencing was done according to the same protocol 
adopted for CTCs.
Sanger sequencing
One microliter of WGA Amplified DNA was 
used for confirmation of selected mutations from the 
analyzed panel by Sanger sequencing. The sequence 
of the primers used for PCR reactions was the same of 
the Ion AmpliSeq™ Cancer Hotspot Panel v2 (Life 
Technologies). The reaction mixture (final volume 20 µl) 
contained 1X PCR Buffer, 0.8 µM dNTPs, 1 µM primers 
and 0.5 U HotStarTaq Plus DNA Polymerase (QIAgen, 
Germany). The thermal profile was: 95°C for 5 min, 
40 cycles at 94°C for 30 sec, 58°C for 30 sec, 72°C 
for 45 sec, then 72°C for 10 min. PCR products were 
purified using the HiYield Gel/PCR DNA Fragments 
Extraction Kit (RBC Bioscience) and sequenced using 
the BigDye Terminator 1.1 CycleSequencing kit (Applied 
Biosystems). Sequence reaction was purified using ZR 
DNA Sequencing Clean-Up Kit (Zymo Research) and 
analyzed using an ABI PRISM 310 Genetic Analyzer 
(Applied Biosystems).
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